Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban for VTE Prevention in AIHA
NCT05089227Phase 2Recruiting
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Feb 2022
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apixaban in venous thromboembolism (VTE), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Started Feb 2022; status: recruiting.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05089227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05089227.